Navigation Links
HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University
Date:6/8/2009

SAN DIEGO, June 8 /PRNewswire/ -- HUYA Bioscience International, a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China, today announced a strategic drug co-development partnership with the Shenyang Pharmaceutical University. The agreement covers a wide range of therapeutic areas and represents one of the first official collaborations of its kind between a U.S. biotech company and a Chinese university.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new pre-clinical and clinical stage compounds. The agreement with Shenyang Pharmaceutical University provides HUYA with rights of first review and negotiation relating to certain novel therapeutic compounds owned or controlled by the University. In return, Shenyang Pharmaceutical University gains access to HUYA's global network of pharmaceutical partners and its expertise in pre-clinical and clinical development.

"Shenyang Pharmaceutical University is a leading pharmaceutical institution with a tradition of innovation," said Mireille Gingras, PhD, President and CEO of HUYA. "We are enthusiastic about collaborating with this University to develop new products for global markets."

Enhancing its collaboration with Shenyang Pharmaceutical University, HUYA has key partnerships with leading global pharmaceutical companies such as Solvay Pharmaceuticals, Abbott, and Schering-Plough. By establishing an extensive global network and world-class drug development capabilities HUYA has become the partner-of-choice for Chinese institutions, universities and biopharma companies looking to maximize the value of their pre-clinical and clinical stage drugs for global markets. HUYA has acquired the development and commercialization rights to two novel development stage drug candidates sourced from China and is developing these candidates in the U.S. for cardiovascular and oncology indications.

"Through our partnership with HUYA, Shenyang Pharmaceutical University looks forward to expanding our international collaborations and gaining broader access to the worldwide markets for our innovative products," said Dr. Shunkai Bi, Vice President of Shenyang Pharmaceutical University.

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance development efficiency and value creation in world-wide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the worldwide value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

About Shenyang Pharmaceutical University

The Shenyang Pharmaceutical University has the longest tradition among China's pharmaceutical universities. It was founded in 1931, and now has over 260 professors and associate professors, over a quarter of who are overseas returnees. It is a national leader in the synthesis and screening of novel pharmaceutical compounds, pharmaceutical formulation development and evaluation, pharmacokinetics and pharmacodynamics, pharmacology and toxicology, and identification and purification of active ingredients from Traditional Chinese Medicines and natural products.

    Contact:

    USA:                               China:
    Bob Giargiari                      Li Zhu, PhD
    EVP Finance and CFO                VP China Operations
    HUYA Bioscience International,     HUYA Bioscience International,
    LLC                                LLC
    (858) 798-8800                     86 (21) 51323312
    bgiargiari@huyabio.com             lzhu@huyabio.com

    Media Contact:

        Juliet Travis
        (510) 452-3771
        juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):